XML 51 R40.htm IDEA: XBRL DOCUMENT
v3.25.1

Segment Data - Revenues by Geographic Areas (Detail) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Mar. 31, 2025 | Mar. 31, 2024 | Mar. 31, 2025 | Mar. 31, 2024
Segment Reporting Information [Line Items] |  |  |  |
Revenues | $ 5,272 | $ 5,045 | $ 10,440 | $ 9,751
Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 2,760 | 2,449 | 5,375 | 4,679
Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,247 | 1,304 | 2,545 | 2,592
Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,264 | 1,292 | 2,521 | 2,480
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 3,108 | 2,906 | 6,187 | 5,655
United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,653 | 1,429 | 3,268 | 2,789
United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 574 | 579 | 1,178 | 1,166
United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 880 | 898 | 1,742 | 1,699
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 2,164 | 2,139 | 4,253 | 4,096
International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,107 | 1,020 | 2,107 | 1,890
International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 673 | 724 | 1,367 | 1,426
International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 384 | 395 | 779 | 781
Medication Delivery Solutions | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 1,117 | 1,107 | 2,241 | 2,159
Medication Delivery Solutions | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 687 | 662 | 1,381 | 1,301
Medication Delivery Solutions | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 430 | 445 | 860 | 857
Medication Management Solutions | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 811 | 772 | 1,612 | 1,518
Medication Management Solutions | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 662 | 609 | 1,321 | 1,203
Medication Management Solutions | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 149 | 162 | 291 | 315
Pharmaceutical Systems | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 575 | 570 | 993 | 1,002
Pharmaceutical Systems | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 149 | 157 | 253 | 285
Pharmaceutical Systems | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 426 | 413 | 740 | 717
Advanced Patient Monitoring | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 257 | 0 | 528 | 0
Advanced Patient Monitoring | United States | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 155 | 0 | 314 | 0
Advanced Patient Monitoring | International | Operating Segments | Medical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 102 | 0 | 215 | 0
Specimen Management | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 456 | 458 | 917 | 905
Specimen Management | United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 242 | 236 | 481 | 469
Specimen Management | International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 213 | 222 | 437 | 436
Diagnostic Solutions | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 440 | 468 | 914 | 935
Diagnostic Solutions | United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 189 | 201 | 402 | 411
Diagnostic Solutions | International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 250 | 267 | 512 | 524
Biosciences | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 352 | 377 | 713 | 752
Biosciences | United States | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 142 | 142 | 295 | 285
Biosciences | International | Operating Segments | Life Sciences |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 209 | 235 | 418 | 466
Surgery | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 383 | 379 | 778 | 748
Surgery | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 289 | 287 | 591 | 568
Surgery | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 94 | 92 | 187 | 181
Peripheral Intervention | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 481 | 489 | 954 | 943
Peripheral Intervention | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 269 | 264 | 522 | 498
Peripheral Intervention | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 212 | 225 | 432 | 444
Urology and Critical Care | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 400 | 424 | 789 | 789
Urology and Critical Care | United States | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | 323 | 347 | 629 | 634
Urology and Critical Care | International | Operating Segments | Interventional |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Revenues | $ 77 | $ 78 | $ 160 | $ 156

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_MedicalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bdx_InterventionalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=us-gaap_NonUsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationDeliverySolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_MedicationManagementSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PharmaceuticalSystemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_AdvancedPatientMonitoringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SpecimenManagementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_DiagnosticSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_BiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_SurgeryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_PeripheralInterventionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | bdx_OrganizationalUnitAxis=bdx_UrologyandCriticalCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |